March 28, 2018 / 12:17 PM / 22 days ago

BRIEF-Bluebird Bio And Celgene Corporation To Co-Develop Anti-Bcma Car T Cell Therapy Bb2121 In The U.S.

March 28 (Reuters) - Bluebird Bio Inc:

* BLUEBIRD BIO AND CELGENE CORPORATION ENTER INTO AGREEMENT TO CO-DEVELOP AND CO-PROMOTE ANTI-BCMA CAR T CELL THERAPY BB2121 IN THE UNITED STATES

* ‍BLUEBIRD AND CELGENE WILL SHARE 50% OF U.S. COSTS AND PROFITS​

* ‍BLUEBIRD TO RECEIVE MILESTONES AND ROYALTIES ON EX-U.S. SALES​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below